SCHEMBL6604236

SCHEMBL6604236

NCCCn1ccc2ccc3ccncc3c21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.60
HTR2C P28335 4/20 0.60
HTR2B P41595 3/20 0.60
P2RX7 Q99572 2/20 0.37
TDP1 Q9NUW8 4/20 0.36
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
ALOX15 P16050 1/20 0.34
STAT6 P42226 1/20 0.34
HIF1A Q16665 1/20 0.34
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
RPS6KA5 O75582 1/20 0.33
HTR1A P08908 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL905906 0.81 HTR2A (0.66) HTR2AHTR2CHTR2BCLK1DYRK1A
SCHEMBL905902 0.75 HTR2C (1.00) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL905948 0.74 HTR2A (0.62) HTR2AHTR2CHTR2BCYP3A4HIF1A
SCHEMBL21245260 0.73 P2RX7 (0.52) P2RX7RPS6KA5MAPTHASPIN
Fumaric Acid SCHEMBL6605771 0.71 HTR2A (0.54) HTR2AHTR2CHTR2BHTR1A
SCHEMBL21245175 0.70 P2RX7 (0.52) P2RX7RPS6KA5HASPIN
Ammonia Solution, Strong SCHEMBL905803 0.69 HTR2A (0.66) HTR2AHTR2CHTR2BHASPIN
SCHEMBL29720987 0.68 GRM2 (0.50) HTR2AHTR2CHTR2BCYP1A2HTR1A
Fumaric Acid SCHEMBL6607435 0.67 HTR2C (0.80) HTR2AHTR2CHTR2B
Fumaric Acid SCHEMBL6605773 0.67 HTR2C (0.80) HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109809-B1 PYRROLOQUINOLINES FOR TREATMENT OF OBESITY CEREBRUS PHARM LTD (GB) 2004-11-17 EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 US disclosed